Central nervous system (CNS) disorders represent one of the largest and most enduring areas of unmet medical need worldwide. Neurodegenerative, neuroinflammatory and genetic neurological diseases continue to impose profound clinical, societal, and economic burdens. Despite meaningful scientific progress over the past decades, therapeutic innovation in CNS has lagged other fields—due in large part to the biological complexity of the brain and the challenges of achieving adequate drug exposure in the central nervous system.
BraneX Bio was founded to address these fundamental limitations. We are an early-stage biotechnology company backed by leading investors and seasoned biotech executives, united by a singular mission: to enable safe, precise, reliable and therapeutically meaningful delivery of advanced medicines to the brain.
Our approach centers on building next-generation precision brain-exposure platforms designed to unlock the full potential of diverse therapeutic modalities, including biologics and other innovative formats. By integrating deep expertise in disease biology, translational science, molecular engineering and development strategy, we aim to systematically expand what is possible in CNS drug development.
Through a focused pipeline of first- and best-in-class programs, BraneX Bio is working to transform how brain diseases are treated—moving beyond incremental progress toward safe, durable, disease-modifying solutions for patients with urgent medical needs.

BraneX Bio （SH）Limited

Org chart

Teams

Offices

BraneX Bio （SH）Limited

Org chart

Teams

Offices

Related companies